Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18827512 | CRYSTALLINE FORMS OF A MENIN INHIBITOR | September 2024 | June 2025 | Allow | 9 | 2 | 0 | No | No |
| 18783334 | CYCLOPROPANE SKELETON MONOPHOSPHINE LIGANDS, PALLADIUM COMPLEXES THEREOF, PREPARATION METHODS AND APPLICATION | July 2024 | March 2025 | Allow | 8 | 0 | 1 | No | No |
| 18765229 | Process for production of essentially pure delta-9-tetrahydrocannabinol | July 2024 | July 2025 | Allow | 13 | 2 | 1 | No | No |
| 18591732 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | February 2024 | May 2025 | Allow | 15 | 0 | 1 | No | No |
| 18588874 | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide | February 2024 | December 2025 | Allow | 22 | 1 | 1 | No | No |
| 18293947 | UREA AND MELAMINE PRODUCTION | January 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18427924 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-1-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | January 2024 | April 2024 | Allow | 3 | 0 | 0 | No | No |
| 18427477 | Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound | January 2024 | November 2025 | Allow | 22 | 1 | 1 | No | No |
| 18395377 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | December 2023 | March 2024 | Allow | 3 | 1 | 0 | No | No |
| 18536859 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | December 2023 | December 2025 | Allow | 24 | 1 | 1 | No | No |
| 18518719 | CRYSTAL FORM OF LANIFIBRANOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | November 2023 | March 2026 | Allow | 28 | 0 | 0 | No | No |
| 18515987 | METHODS AND FORMULATIONS FOR REDUCING BOVINE EMISSIONS | November 2023 | March 2026 | Allow | 28 | 1 | 0 | No | No |
| 18560665 | REAGENTS AND METHODS FOR ALIPHATIC CARBON-HYDROGEN BOND FUNCTIONALIZATION | November 2023 | November 2025 | Allow | 24 | 3 | 1 | No | No |
| 18558726 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | November 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18383128 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | October 2023 | August 2025 | Allow | 21 | 1 | 1 | No | No |
| 18383144 | Choline Salt Forms of an HIV Capsid Inhibitor | October 2023 | January 2026 | Allow | 27 | 1 | 0 | No | No |
| 18490700 | COMPOSITIONS AND METHODS FOR TREATING CANCER | October 2023 | June 2024 | Allow | 7 | 1 | 1 | Yes | No |
| 18287040 | ALPHA2 ADRENERGIC AGONIST CODRUGS CONJUGATED WITH MUSCARINIC AGONIST DRUGS | October 2023 | January 2026 | Allow | 27 | 0 | 0 | No | No |
| 18486813 | N'-(1-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 1 | No | No |
| 18486921 | 2-ALKOXY[4,3:6,2-TERPYRIDINE]-3-CARBONITRILE AS ANTIMICROBIAL COMPOUNDS | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18379024 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 1 | No | No |
| 18378785 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-1-NAPHTHIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 1 | No | No |
| 18484185 | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators | October 2023 | January 2026 | Abandon | 27 | 1 | 1 | No | No |
| 18377656 | POLYMORPHIC FORMS OF CYCLO (-HIS-PRO) AND METHODS OF USE TO TREAT KIDNEY DISEASE | October 2023 | September 2025 | Allow | 24 | 2 | 1 | No | No |
| 18476137 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | September 2023 | August 2025 | Allow | 22 | 1 | 1 | No | No |
| 18470331 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them | September 2023 | June 2025 | Allow | 21 | 1 | 1 | No | No |
| 18461093 | SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS | September 2023 | March 2025 | Allow | 18 | 1 | 1 | No | No |
| 18360909 | COMPOUNDS AND COMPOSITIONS FOR TREATING SOLID TUMORS BY INTRATUMORAL ADMINISTRATION | July 2023 | October 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18221546 | SYNTHESIS OF HETEROCYCLIC COMPOUNDS | July 2023 | June 2025 | Allow | 23 | 1 | 1 | No | No |
| 18217874 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | July 2023 | December 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18211772 | PROCESSES FOR MAKING MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | June 2023 | February 2024 | Allow | 8 | 0 | 0 | No | No |
| 18335032 | ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR REDUCING REDNESS AND INCREASING WHITENESS IN EYES AND OTHER OPHTHALMIC PURPOSES | June 2023 | July 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18325214 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | May 2023 | October 2024 | Allow | 17 | 1 | 1 | No | No |
| 18324050 | METHODS OF TREATING CANCER WITH AN MTOR INHIBITOR | May 2023 | September 2025 | Allow | 28 | 0 | 0 | No | No |
| 18318960 | CORROSION INHIBITOR FORMULATIONS BASED ON COMPOUNDS WITH BOTH PYRIDINIUM AND HYDROXY SUBSTITUENTS | May 2023 | December 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 18037253 | SRC INHIBITORS AND USES THEREOF | May 2023 | March 2026 | Abandon | 34 | 0 | 1 | No | No |
| 18195142 | COMPOSITIONS AND METHODS FOR OPIOID ANTAGONIST DELIVERY | May 2023 | November 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18304153 | METHOD FOR TREATING VASO OCCLUSIVE CRISES ASSOCIATED WITH SICKLE CELL DISEASE | April 2023 | January 2026 | Allow | 33 | 1 | 0 | No | No |
| 18249584 | A METHOD FOR INCREASING PROPYLENE OXIDE OUTPUT OF AN INTEGRATED PROCESS FOR MAKING PROPYLENE OXIDE AND PROPYLENE GLYCOL | April 2023 | December 2025 | Allow | 32 | 0 | 0 | No | No |
| 18030302 | IMDQ-PEG-CHOL ADJUVANT AND USES THEREOF | April 2023 | October 2025 | Allow | 30 | 0 | 0 | No | No |
| 18120167 | JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF | March 2023 | January 2026 | Allow | 34 | 1 | 1 | No | No |
| 18043987 | PHOSPHONATE PRODUCTS AND METHODS | March 2023 | November 2024 | Allow | 20 | 1 | 1 | No | No |
| 18115767 | NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES | February 2023 | March 2026 | Allow | 37 | 1 | 0 | No | No |
| 18042002 | BORACIC ACID COMPOUND | February 2023 | November 2025 | Allow | 33 | 0 | 1 | No | No |
| 18018459 | Acrylamide-Substituted Indane Compounds and Therapeutic Use Thereof | January 2023 | July 2025 | Allow | 30 | 0 | 0 | No | No |
| 18096471 | KIT FOR MIGRAINE MANAGEMENT | January 2023 | February 2026 | Abandon | 37 | 0 | 1 | No | No |
| 17759305 | METHOD FOR EVALUATING QUALITY OF (3S)-3-(4-(3-(1,4-DIOXASPIRO[4,5]DEC-7-EN-8-YL)BENZYLOXY)PHENYL)HEX-4-INOIC ACID | January 2023 | October 2025 | Allow | 39 | 0 | 0 | No | No |
| 18090722 | SYSTEMS AND METHODS FOR INCREASING STABILITY OF DRONABINOL COMPOSITIONS | December 2022 | February 2025 | Allow | 25 | 2 | 1 | No | No |
| 18013412 | COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING DISEASE CAUSED BY NITRATION OF TYROSINE IN PROTEINS COMPRISING TYROSINE AS EFFECTIVE COMPONENT | December 2022 | March 2026 | Allow | 38 | 2 | 0 | No | No |
| 18089065 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | December 2022 | May 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18070827 | PROCESS FOR SYNTHESIS OF 2-AMINO-5-CHLORO-N-,3-DIMETHYLBENZAMIDE | November 2022 | June 2024 | Allow | 18 | 1 | 1 | No | No |
| 18058655 | COMPOSITIONS AND METHODS FOR TREATING CANCER | November 2022 | October 2023 | Allow | 10 | 1 | 1 | No | No |
| 17992049 | Heterocyclic Compounds as RET Kinase Inhibitors | November 2022 | December 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17991558 | THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA | November 2022 | September 2024 | Allow | 22 | 1 | 0 | No | No |
| 17990939 | SYNTHETIC PROCESS AND NOVEL INTERMEDIATES | November 2022 | March 2024 | Abandon | 16 | 0 | 1 | No | No |
| 17925873 | PREPARATION OF SUBSTITUTED 4-(N'-HYDROXYCARBAMIMIDOYL)BENZOIC ACIDS | November 2022 | August 2025 | Allow | 33 | 1 | 1 | No | No |
| 18053197 | HYDROCHLOROTHIAZIDE COMPOSITIONS | November 2022 | November 2023 | Allow | 12 | 2 | 1 | No | No |
| 18050743 | Preparation Methods and Uses of Purified Fulvic Acid | October 2022 | November 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17997135 | NEW TRIAZINOINDOLE COMPOUNDS | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17972220 | METHODS FOR THE SYNTHESIS OF ACTIVATED ETHYLFUMARATES AND THEIR USE AS INTERMEDIATES | October 2022 | September 2024 | Allow | 22 | 1 | 1 | No | No |
| 17996844 | REGIOSELECTIVE OXIDATION OF HETEROCYCLIC ALPHA-AMINO AMIDES | October 2022 | November 2025 | Abandon | 37 | 0 | 1 | No | No |
| 18047289 | COMPOSITIONS COMPRISING CIPROFLOXACIN AND CELECOXIB | October 2022 | June 2024 | Allow | 20 | 0 | 1 | No | No |
| 18046244 | NEUROSTEROIDS AND ENANTIOMERS THEREOF FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE CONDITIONS | October 2022 | October 2025 | Allow | 37 | 3 | 1 | No | No |
| 17995857 | AN IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE SIDE CHAIN | October 2022 | August 2025 | Allow | 34 | 0 | 0 | No | No |
| 17909317 | METHOD FOR PRODUCING NAPHTHYLSILOLE, NAPHTHYLSILOLE CONTAINING HETEROCYCLIC GROUP, AND GRAPHENE NANORIBBON CONTAINING HETEROCYCLIC GROUP | October 2022 | January 2026 | Allow | 41 | 2 | 1 | No | No |
| 17960046 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | October 2022 | August 2024 | Allow | 22 | 2 | 1 | No | No |
| 17914699 | NOVEL BENZIMIDAZOLE DERIVATIVE | September 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17913883 | STABLE HEAVY ISOTOPES IN AMIDE FUNCTIONAL GROUPS AND USES THEREOF | September 2022 | March 2025 | Allow | 30 | 1 | 1 | No | No |
| 17950902 | Pharmaceutical Formulations Containing Relacorilant, a Heteroaryl-Ketone Fused Azadecalin Compound | September 2022 | December 2023 | Allow | 15 | 1 | 1 | No | No |
| 17946635 | Cannabinoid Product for Improvement of Sleep | September 2022 | January 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17905797 | NOVEL LAPPACONITINE DERIVATIVE AND USE THEREOF | September 2022 | August 2025 | Allow | 36 | 0 | 1 | No | No |
| 17909916 | BCL-2 FAMILY PROTEINS MODULATING COMPOUNDS FOR CANCER TREATMENT | September 2022 | February 2026 | Allow | 41 | 1 | 1 | No | No |
| 17908203 | OPIOID RECEPTOR ANTAGONISTS | August 2022 | January 2026 | Allow | 41 | 1 | 1 | No | No |
| 17802557 | Potassium salt of 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid | August 2022 | December 2025 | Allow | 40 | 1 | 0 | No | No |
| 17929027 | PREPARATION OF A P2X3 ANTAGONIST | August 2022 | May 2025 | Allow | 33 | 0 | 0 | No | No |
| 17884154 | TERNARY PHOTOACTIVE LAYER COMPOSITION AND ORGANIC SOLAR CELL COMPRISING SAME | August 2022 | June 2025 | Allow | 34 | 0 | 1 | No | No |
| 17797643 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PRURITUS | August 2022 | November 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17760143 | PYRROLO[2,3-b]PYRIDINE-3-CARBOXAMIDE COMPOSITIONS AND METHODS FOR AMELIORATING HEARING LOSS | August 2022 | December 2025 | Allow | 41 | 1 | 1 | No | No |
| 17759467 | METHODS OF TREATING AND ASSESSING PULMONARY ARTERIAL HYPERTENSION WITH SELEXIPAG | July 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17858917 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | July 2022 | September 2024 | Allow | 26 | 2 | 1 | No | No |
| 17810214 | SUBSTITUTED THIOPHENECARBOXAMIDES AND ANALOGUES AS ANTIBACTERIALS AGENTS | June 2022 | December 2023 | Allow | 17 | 0 | 1 | No | No |
| 17787389 | ORGANIC ELECTRON TRANSFER MEDIATOR AND DEVICE COMPRISING SAME | June 2022 | December 2025 | Allow | 42 | 1 | 1 | No | No |
| 17757653 | A NEW METHOD OF 18F LABELLING AND INTERMEDIATE SALTS | June 2022 | March 2026 | Abandon | 45 | 1 | 1 | No | No |
| 17786647 | JAK KINASE INHIBITOR PHARMACEUTICAL COMPOSITION | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17785842 | CAI NANOEMULSIONS | June 2022 | January 2026 | Allow | 43 | 1 | 1 | No | No |
| 17785612 | Aggregation Inhibitory Agent and Medical Composition and Medical Device Including Same | June 2022 | November 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17784971 | MONOBACTAM COMPOUND AND USE THEREOF | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17806395 | SYNTHESIS OF FMOC-PROTECTED MORPHOLINO MONOMERS AND OLIGOMERS | June 2022 | April 2024 | Allow | 22 | 2 | 1 | No | No |
| 17784368 | METHOD FOR SYNTHESIZING ZIRCONIUM COMPLEX | June 2022 | February 2026 | Allow | 45 | 1 | 1 | Yes | No |
| 17804566 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | May 2022 | October 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17637637 | BENZIMIDAZOLE SUBSTITUTION-BASED PHENYL N-BUTYRAMIDE COMPOUND AND PREPARATION METHOD THEREFOR | May 2022 | July 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17779804 | PENICILLIN-BINDING PROTEIN INHIBITORS | May 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17777536 | PYRAZOLOMORPHINAN DERIVATIVE | May 2022 | September 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17776937 | PREPARATION OF TETRADENTATE PLATINUM(II) COMPLEX AND USE THEREOF | May 2022 | September 2025 | Allow | 40 | 1 | 0 | No | No |
| 17776934 | SMALL MOLECULES POLYMERASE INHIBITORS | May 2022 | November 2025 | Allow | 42 | 1 | 1 | No | No |
| 17742843 | Solid Oral Dosage Forms Of Dexamethasone | May 2022 | December 2023 | Abandon | 19 | 0 | 1 | No | No |
| 17739099 | NAIL HARDENING COMPOSITION AND METHOD OF USE | May 2022 | December 2022 | Allow | 7 | 1 | 1 | No | No |
| 17737273 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF CARBAPROSTACYCLIN ANALOGUES | May 2022 | September 2023 | Allow | 16 | 0 | 1 | No | No |
| 17737113 | PHENYL AND PYRIDINYL SUBSTITUTED IMIDAZOLES AS MODULATORS OF RORgT | May 2022 | July 2023 | Abandon | 15 | 0 | 1 | No | No |
| 17737408 | MULTI-STAGE ESTERIFICATION PROCESS | May 2022 | October 2023 | Abandon | 18 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KENYON, JOHN S.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 46.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner KENYON, JOHN S works in Art Unit 1625 and has examined 760 patent applications in our dataset. With an allowance rate of 78.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner KENYON, JOHN S's allowance rate of 78.2% places them in the 46% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by KENYON, JOHN S receive 1.63 office actions before reaching final disposition. This places the examiner in the 32% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KENYON, JOHN S is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +27.0% benefit to allowance rate for applications examined by KENYON, JOHN S. This interview benefit is in the 74% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 32.1% of applications are subsequently allowed. This success rate is in the 67% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 56.5% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 90.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 62.7% are granted (fully or in part). This grant rate is in the 67% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 66% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.